28.93
price up icon3.65%   1.02
after-market アフターアワーズ: 28.93
loading
前日終値:
$27.91
開ける:
$28.41
24時間の取引高:
960.05K
Relative Volume:
1.13
時価総額:
$1.87B
収益:
$32.08M
当期純損益:
$-169.77M
株価収益率:
-10.18
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
-1.40%
1か月 パフォーマンス:
-9.96%
6か月 パフォーマンス:
-11.99%
1年 パフォーマンス:
+27.22%
1日の値動き範囲:
Value
$28.36
$29.13
1週間の範囲:
Value
$27.66
$30.16
52週間の値動き範囲:
Value
$20.32
$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
名前
Stoke Therapeutics Inc
Name
セクター
Healthcare (1072)
Name
電話
781-430-8200
Name
住所
45 WIGGINS AVENUE, BEDFORD, MA
Name
職員
170
Name
Twitter
@stoketx
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
STOK icon
STOK
Stoke Therapeutics Inc
28.93 1.87B 32.08M -169.77M -147.70M -2.8418
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
516.34 130.64B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
789.45 80.46B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
158.07 57.48B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
995.77 61.58B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
196.94 43.68B 742.00K -1.37B -1.07B -7.0731

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-02-05 開始されました Guggenheim Buy
2026-01-05 再開されました Chardan Capital Markets Buy
2025-07-18 開始されました Jefferies Buy
2024-12-20 開始されました Chardan Capital Markets Buy
2024-10-14 再開されました Leerink Partners Outperform
2024-03-26 アップグレード TD Cowen Market Perform → Outperform
2023-11-20 再開されました JP Morgan Neutral
2023-07-25 ダウングレード TD Cowen Outperform → Market Perform
2023-05-01 アップグレード BofA Securities Underperform → Neutral
2023-04-26 再開されました Canaccord Genuity Buy
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2022-10-24 アップグレード SVB Leerink Mkt Perform → Outperform
2022-01-31 開始されました Jefferies Buy
2021-12-03 開始されました BofA Securities Buy
2021-11-22 アップグレード JP Morgan Neutral → Overweight
2021-05-18 開始されました UBS Neutral
2021-05-10 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-02-10 ダウングレード Wedbush Outperform → Neutral
2020-12-15 再開されました H.C. Wainwright Buy
2020-12-11 繰り返されました Needham Buy
2020-10-23 開始されました Cantor Fitzgerald Overweight
2020-09-29 再開されました JP Morgan Neutral
2020-09-29 開始されました Needham Buy
2019-12-18 開始されました Wedbush Outperform
2019-11-12 開始されました BTIG Research Buy
2019-10-25 開始されました H.C. Wainwright Buy
2019-07-15 開始されました Canaccord Genuity Buy
2019-07-15 開始されました Cowen Outperform
2019-07-15 開始されました Credit Suisse Outperform
2019-07-15 開始されました JP Morgan Overweight
すべてを表示

Stoke Therapeutics Inc (STOK) 最新ニュース

pulisher
Sep 11, 2026

Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us

Sep 11, 2026
pulisher
Sep 10, 2026

Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com

Sep 10, 2026
pulisher
Sep 10, 2026

Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria

Sep 10, 2026
pulisher
Sep 09, 2026

Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India

Sep 09, 2026
pulisher
Sep 09, 2026

STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

Stoke Therapeutics (STOK) Institutional Ownership 2026 $STOK - MarketBeat

Sep 09, 2026
pulisher
Sep 08, 2026

Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat

Sep 08, 2026
pulisher
Sep 06, 2026

Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat

Sep 06, 2026
pulisher
Sep 05, 2026

Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat

Sep 05, 2026
pulisher
Sep 04, 2026

Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review

Sep 04, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media

Sep 03, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics grants inducement options to new CSO - scanx.trade

Sep 03, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - manilatimes.net

Sep 03, 2026
pulisher
Sep 03, 2026

Biogen Inc. - Via Ritzau

Sep 03, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan

Sep 03, 2026
pulisher
Sep 03, 2026

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo

Sep 03, 2026
pulisher
Sep 03, 2026

The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de

Sep 03, 2026
pulisher
Sep 02, 2026

BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill

Sep 02, 2026
pulisher
Sep 02, 2026

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance

Sep 02, 2026
pulisher
Sep 02, 2026

Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat

Sep 02, 2026
pulisher
Sep 01, 2026

Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria

Sep 01, 2026
pulisher
Sep 01, 2026

Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com

Sep 01, 2026
pulisher
Aug 29, 2026

57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG - marketbeat.com

Aug 29, 2026
pulisher
Aug 29, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 29, 2026
pulisher
Aug 28, 2026

Palo Alto Investors LP Invests $2.77 Million in Stoke Therapeutics, Inc. $STOK - marketbeat.com

Aug 28, 2026
pulisher
Aug 28, 2026

Jupiter Topco LLC Takes $59.36 Million Position in Stoke Therapeutics, Inc. $STOK - marketbeat.com

Aug 28, 2026
pulisher
Aug 28, 2026

BlackRock Inc. Buys Shares of 5,877,357 Stoke Therapeutics, Inc. $STOK - marketbeat.com

Aug 28, 2026
pulisher
Aug 25, 2026

Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Aug 25, 2026
pulisher
Aug 24, 2026

Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight - Yahoo Finance

Aug 24, 2026
pulisher
Aug 21, 2026

STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView

Aug 21, 2026
pulisher
Aug 21, 2026

STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada

Aug 21, 2026
pulisher
Aug 21, 2026

Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance

Aug 21, 2026
pulisher
Aug 20, 2026

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - vinanet.vn

Aug 20, 2026
pulisher
Aug 19, 2026

Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st

Aug 19, 2026
pulisher
Aug 19, 2026

Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - vinanet.vn

Aug 19, 2026
pulisher
Aug 19, 2026

Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia

Aug 19, 2026
pulisher
Aug 18, 2026

Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat

Aug 18, 2026

Stoke Therapeutics Inc (STOK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$58.93
price up icon 0.79%
$123.98
price up icon 1.14%
$39.98
price up icon 1.04%
$245.51
price up icon 2.57%
ONC ONC
$353.46
price up icon 1.55%
$196.94
price up icon 0.52%
大文字化:     |  ボリューム (24 時間):